Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index.

Zell JA, McLaren CE, Morgan TR, Lawson MJ, Rezk S, Albers CG, Chen WP, Carmichael JC, Chung J, Richmond E, Rodriguez LM, Szabo E, Ford LG, Pollak MN, Meyskens FL.

Cancer Prev Res (Phila). 2020 Feb;13(2):203-212. doi: 10.1158/1940-6207.CAPR-18-0262. Epub 2019 Dec 9.

PMID:
31818851
2.

Trends in Medical Aid in Dying in Oregon and Washington.

Al Rabadi L, LeBlanc M, Bucy T, Ellis LM, Hershman DL, Meyskens FL Jr, Taylor L, Blanke CD.

JAMA Netw Open. 2019 Aug 2;2(8):e198648. doi: 10.1001/jamanetworkopen.2019.8648.

3.

Abscopal Outcomes: Reflections on Distant Effects.

Meyskens FL Jr.

Pract Radiat Oncol. 2019 Sep - Oct;9(5):294. doi: 10.1016/j.prro.2019.05.002. Epub 2019 May 16. No abstract available.

4.

Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential Mechanisms of Early- and Late-Onset Melanoma.

Yuan TA, Lu Y, Edwards K, Jakowatz J, Meyskens FL, Liu-Smith F.

Int J Environ Res Public Health. 2019 Mar 13;16(6). pii: E908. doi: 10.3390/ijerph16060908.

5.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS.

J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185.

6.

Oxidative stress and antioxidants in the pathophysiology of malignant melanoma.

Obrador E, Liu-Smith F, Dellinger RW, Salvador R, Meyskens FL, Estrela JM.

Biol Chem. 2019 Apr 24;400(5):589-612. doi: 10.1515/hsz-2018-0327. Review.

7.

12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma.

Laquer V, Dellinger RW, Mannering I, Garcia AG, Abraham V, Pavlis J, Liu-Smith F, De Feraudy S, Meyskens FL Jr, Kelly KM.

J Am Acad Dermatol. 2018 Dec;79(6):1152-1153. doi: 10.1016/j.jaad.2018.05.1251. Epub 2018 Jun 11. No abstract available.

8.

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.

Zecena H, Tveit D, Wang Z, Farhat A, Panchal P, Liu J, Singh SJ, Sanghera A, Bainiwal A, Teo SY, Meyskens FL Jr, Liu-Smith F, Filipp FV.

BMC Syst Biol. 2018 Apr 4;12(1):33. doi: 10.1186/s12918-018-0554-1.

9.

A cancer registry-based analysis on the non-white populations reveals a critical role of the female sex in early-onset melanoma.

Yuan TA, Meyskens F, Liu-Smith F.

Cancer Causes Control. 2018 May;29(4-5):405-415. doi: 10.1007/s10552-018-1022-3. Epub 2018 Mar 9.

10.

Oregon's Death With Dignity Act-Reply.

Blanke C, Ellis L, Meyskens F.

JAMA Oncol. 2018 May 1;4(5):748. doi: 10.1001/jamaoncol.2017.5323. No abstract available.

PMID:
29450455
11.

A Case-Control Study of the Genetic Variability in Reactive Oxygen Species-Metabolizing Enzymes in Melanoma Risk.

Yuan TA, Yourk V, Farhat A, Ziogas A, Meyskens FL, Anton-Culver H, Liu-Smith F.

Int J Mol Sci. 2018 Jan 14;19(1). pii: E242. doi: 10.3390/ijms19010242.

12.

Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis.

Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL Jr, Andresen BT, Huang Y.

Cancer Prev Res (Phila). 2017 Oct;10(10):598-606. doi: 10.1158/1940-6207.CAPR-17-0132. Epub 2017 Aug 15.

13.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK.

Melanoma Manag. 2017 Mar;4(1):13-37. doi: 10.2217/mmt-2016-0022. Epub 2017 Mar 1. Review.

14.

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.

Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, Albain KS.

NPJ Breast Cancer. 2016 Aug 10;2:16024. doi: 10.1038/npjbcancer.2016.24. eCollection 2016.

15.

Redox-Redux and NADPH Oxidase (NOX): Even More Complicated than We Thought it Might Be.

Meyskens FL Jr, Liu-Smith F.

J Invest Dermatol. 2017 Jun;137(6):1208-1210. doi: 10.1016/j.jid.2017.01.019. Review.

16.

Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure.

Liu-Smith F, Farhat AM, Arce A, Ziogas A, Taylor T, Wang Z, Yourk V, Liu J, Wu J, McEligot AJ, Anton-Culver H, Meyskens FL.

J Am Acad Dermatol. 2017 Mar;76(3):499-505.e3. doi: 10.1016/j.jaad.2016.08.027. Epub 2016 Oct 26.

17.

Characterizing 18 Years of the Death With Dignity Act in Oregon.

Blanke C, LeBlanc M, Hershman D, Ellis L, Meyskens F.

JAMA Oncol. 2017 Oct 1;3(10):1403-1406. doi: 10.1001/jamaoncol.2017.0243. Erratum in: JAMA Oncol. 2017 Oct 1;3(10):1431. JAMA Oncol. 2017 Oct 1;3(10):1431.

18.

What to Do With the Participants/Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA.

Meyskens FL Jr.

J Natl Cancer Inst. 2016 Dec 16;108(12). pii: djw252. Print 2016 Dec. No abstract available.

19.

Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.

Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL.

Trials. 2016 Aug 12;17:400. doi: 10.1186/s13063-016-1524-9.

20.

Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity.

Uchio E, Meyskens FL, Wang PH.

Cancer Prev Res (Phila). 2016 Oct;9(10):777-778. Epub 2016 Jul 18. No abstract available.

21.

Measuring Redox Status of Melanoma Cells.

Liu-Smith F, Krasieva TB, Liu J, Liu J, Meyskens FL Jr.

Methods Mol Biol. 2016 Apr 10. [Epub ahead of print]

22.

Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma.

Liu-Smith F, Meyskens FL.

Mol Nutr Food Res. 2016 Jun;60(6):1264-74. doi: 10.1002/mnfr.201500822. Epub 2016 Mar 21. Review.

23.

Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells.

Dellinger RW, Meyskens FL Jr.

Methods Mol Biol. 2016 Jan 20. [Epub ahead of print]

PMID:
26786882
24.

Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals.

Meyskens FL Jr.

Cancer Prev Res (Phila). 2016 Jan;9(1):11-2. doi: 10.1158/1940-6207.CAPR-15-0401. Epub 2015 Dec 23. No abstract available.

25.

Melanoma Epidemiology and Prevention.

Berwick M, Buller DB, Cust A, Gallagher R, Lee TK, Meyskens F, Pandey S, Thomas NE, Veierød MB, Ward S.

Cancer Treat Res. 2016;167:17-49. doi: 10.1007/978-3-319-22539-5_2. Review.

PMID:
26601858
26.

Cancer Prevention: Obstacles, Challenges and the Road Ahead.

Meyskens FL Jr, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS.

J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv309. doi: 10.1093/jnci/djv309. Print 2016 Feb. Review.

27.

Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group.

Fabian CJ, Meyskens FL Jr, Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr.

J Clin Oncol. 2016 Jan 10;34(2):186-93. doi: 10.1200/JCO.2015.63.5979. Epub 2015 Nov 2.

28.

A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Morgan TR, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu KQ, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL.

Cancer Prev Res (Phila). 2015 Sep;8(9):864-72. doi: 10.1158/1940-6207.CAPR-15-0029. Epub 2015 Jun 30.

29.

Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.

Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew DL, Hansen LK, Meyskens FL Jr, Wade JL 3rd, Hershman DL.

J Acupunct Meridian Stud. 2015 Jun;8(3):152-8. doi: 10.1016/j.jams.2015.03.006. Epub 2015 Apr 23.

30.

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM.

J Clin Oncol. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4.

31.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators.

N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204.

32.

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.

Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM.

Cancer Prev Res (Phila). 2015 Mar;8(3):222-30. doi: 10.1158/1940-6207.CAPR-14-0148. Epub 2015 Jan 20.

33.

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.

34.

Amyloids, melanins and oxidative stress in melanomagenesis.

Liu-Smith F, Poe C, Farmer PJ, Meyskens FL Jr.

Exp Dermatol. 2015 Mar;24(3):171-4. doi: 10.1111/exd.12559. Epub 2014 Nov 18.

35.

The role of APE/Ref-1 signaling pathway in hepatocellular carcinoma progression.

Yang Z, Yang S, Misner BJ, Liu-Smith F, Meyskens FL.

Int J Oncol. 2014 Nov;45(5):1820-8. doi: 10.3892/ijo.2014.2589. Epub 2014 Aug 8.

36.

Estimates of benefits and harms of prophylactic use of aspirin in the general population.

Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A.

Ann Oncol. 2015 Jan;26(1):47-57. doi: 10.1093/annonc/mdu225. Epub 2014 Aug 5. Review.

37.

Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1638-48. doi: 10.1158/1055-9965.EPI-14-0202. Epub 2014 Jul 15.

38.

Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis.

Dellinger RW, Liu-Smith F, Meyskens FL Jr.

J Photochem Photobiol B. 2014 Sep 5;138:317-23. doi: 10.1016/j.jphotobiol.2014.06.006. Epub 2014 Jun 20. Review.

39.

Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL Jr, Thompson IM.

Cancer Prev Res (Phila). 2014 Sep;7(9):886-95. doi: 10.1158/1940-6207.CAPR-14-0058. Epub 2014 Jun 24.

40.

Updates of reactive oxygen species in melanoma etiology and progression.

Liu-Smith F, Dellinger R, Meyskens FL Jr.

Arch Biochem Biophys. 2014 Dec 1;563:51-5. doi: 10.1016/j.abb.2014.04.007. Epub 2014 Apr 26. Review.

41.

Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial.

Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1494-504. doi: 10.1158/1055-9965.EPI-14-0115. Epub 2014 Apr 14.

42.

A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.

Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL Jr.

Cancer Prev Res (Phila). 2014 May;7(5):496-504. doi: 10.1158/1940-6207.CAPR-13-0189. Epub 2014 Mar 10.

43.

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA.

J Natl Cancer Inst. 2014 Mar;106(3):djt456. doi: 10.1093/jnci/djt456. Epub 2014 Feb 22.

44.

Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.

Meyskens FL Jr, Simoneau AR, Gerner EW.

Recent Results Cancer Res. 2014;202:115-20. doi: 10.1007/978-3-642-45195-9_14.

PMID:
24531785
45.

Potent and selective double-headed thiophene-2-carboximidamide inhibitors of neuronal nitric oxide synthase for the treatment of melanoma.

Huang H, Li H, Yang S, Chreifi G, Martásek P, Roman LJ, Meyskens FL, Poulos TL, Silverman RB.

J Med Chem. 2014 Feb 13;57(3):686-700. doi: 10.1021/jm401252e. Epub 2014 Jan 30.

46.

Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences.

Dellinger RW, Garcia AM, Meyskens FL Jr.

Drug Metab Pharmacokinet. 2014;29(2):112-9. Epub 2013 Aug 20.

47.

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR.

J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41. doi: 10.1093/jnci/djt174. Epub 2013 Jul 10.

48.

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS.

J Clin Oncol. 2013 Jul 10;31(20):2627-33. doi: 10.1200/JCO.2012.44.8738. Epub 2013 Jun 3.

49.

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL Jr.

Cancer Prev Res (Phila). 2013 May;6(5):410-8. doi: 10.1158/1940-6207.CAPR-13-0004.

50.

The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines.

Xie L, Meyskens FL Jr.

Melanoma Res. 2013 Apr;23(2):102-13. doi: 10.1097/CMR.0b013e32835df5e4.

Supplemental Content

Loading ...
Support Center